Published in Blood Weekly, November 20th, 2003
According to published research from the United States, "A high incidence of nonrelapse mortality (NRM) has limited the use of allogeneic transplantation" for NHL patients with poor prognosis.
In a recent study, S. Seropian and coauthors at Yale University "sought to improve the outcome of allografting by utilizing filgrastim-mobilized peripheral blood stem cells (PBSC) in combination with either standard ablative or reduced-intensity conditioning."
"A total of 21 patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.